Cyd Tdv | List of Frontiers open access articles

Review

Published on 04 Aug 2017

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis

in Microbial Immunology

Moffat Malisheni
Svetlana F. Khaiboullina
Albert A. Rizvanov
Noah Takah
Grant Murewanhema
Matthew Bates

Frontiers in Immunology

doi 10.3389/fimmu.2017.00863

11,125 views
29 citations

Original Research

Published on 20 Feb 2026

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database

in Pharmacology of Infectious Diseases

Viviana Maria Gianguzzo
Michelangelo Rottura
Federica Maria Sacco
Matthew Gavino Donadu
Giuseppina Sanna
Natasha Irrera
Egidio Imbalzano
Vincenzo Arcoraci
Giuseppinella Melita
Ylenia Marino

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1789762

247 views

Original Research

Published on 02 Feb 2017

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

in Drugs Outcomes Research and Policies

Isabella P. Godói
André S. Santos
Edna A. Reis
Livia L. P. Lemos
Cristina M. R. Brandão
Juliana Alvares
Francisco A. Acurcio
Brian Godman
Augusto A. Guerra Júnior

Frontiers in Pharmacology

doi 10.3389/fphar.2017.00041

15,728 views
42 citations

Original Research

Published on 08 Aug 2025

The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement

in Virology

Tianran Zhang
Yaqi Shi
Leyi Zhang
Jian Wang
Chengchao Yu
Binbin Lv
Sisi Wu
Yiru Huang
Xuewei Liu
Hupiao Dai

Frontiers in Microbiology

doi 10.3389/fmicb.2025.1607085

4,124 views

Review

Published on 24 Feb 2022

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

in Vaccines and Molecular Therapeutics

Jue Hou
Weijian Ye
Jianzhu Chen

Frontiers in Immunology

doi 10.3389/fimmu.2022.840104

20,839 views
53 citations

Review

Published on 14 Feb 2023

Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach

in Molecular Viral Pathogenesis

Harun Norshidah
Chiuan Herng Leow
Kamarulzaman Ezatul Ezleen
Habibah A. Wahab
Ramachandran Vignesh
Azhar Rasul
Ngit Shin Lai

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2023.1061937

17,494 views
36 citations

Articles

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach